Logo Image
|Articles|March 6, 2017

CPhI North America Releases Conference Program Lineup

The conference will include 55 speakers at more than 44 sessions.

The first CPhI North America conference will take place in Philadelphia, PA from May 16–18, 2017. As part of the conference, CPhI will launch the Connect Conference, featuring two educational programs, CPhI Connect, focused on pharmaceuticals, and InformEx connect, focused on fine and specialty chemicals.

The Connect Conference includes 55 speakers at more than 44 sessions across eight tracks. Delegates of the Connect Conference will have access to both programs with one pass. CPhI Connect will contain four tracks, drug development, quality/regulation, drug manufacturing, and outsourcing. The program will offer perspectives on an assortment of topics in the bio/pharmaceutical industries. The following is a sampling of some of the conference speakers:

  • Magid Abou-Gharbia, PhD, FRSC, associate dean for Research, Laura H. Carnell professor of Medicinal Chemistry & Director of the Moulder Center for Drug Discovery Research (MCDDR), School of Pharmacy, Temple University

  • Sunny Bhardwaj, senior scientist, Merck

  • Richard D. Braatz, PhD, Edwin R. Gilliland professor of Chemical Engineering, Massachusetts Institute of Technology

  • David Conlon, senior principal scientist, Bristol-Myers Squibb

  • Ian W. Davies, Department of Process and Analytical Chemistry, Merck Research Laboratories, Merck and Co. Inc.

  • Amy Ethier, PhD, formulation scientist, Skin Delivery, BASF Pharma Solutions

  • Robert Garbaccio, executive director, Merck

  • Stephen V. Hammond, senior director/team leader of the Process Analytical Sciences Group, Pfizer Global Technology

  • Antonio Hernandez-Cardoso, senior scientific liaison, United States Pharmacopeia

  • Jim Lalonde, senior vice-president of R&D, Codexis Inc.

  • D. Jeffery Liu, PhD, MBA, MS, director/clinical development head, ID/IIDPH, RD, GlaxoSmithKline

  • Ronald T. Piervincenzi, PhD, CEO, US Pharmacopeial Convention 

  • Yihong Qiu, Oral Drug Products, Manufacturing Science & Technology, AbbVie, Inc.

  • David Rabuka, PhD, Global Head of R&D, Chemical Biology, Catalent Biologics–West (formerly Redwood Bioscience), Catalent Pharma Solutions

  • Peter D. Senter, PhD, vice-president, Chemistry and Senior Distinguished Fellow, Seattle Genetics

  • Satish K. Singh, Drug Product Services, Lonza Pharma and Biotech, Lonza Ltd.

  • Arvind Srivastava, PhD, Research Advisor, Formulation Development, CMC Development, Eli Lilly and Company

  • Pete Stevenson, vice-president and general manager, Pfizer CentreOne

  • Tom Wilson, vice-president, Contract Manufacturing Operations, Pfizer Global Supply & Pfizer CentreOne

  • Ron Vladyka, director of Research & Development, Catalent Pharma Solutions.

Participants in CPhI Connect will also have access to the expo floor featuring more than 450 companies across the pharma supply chain, as well as show floor programming and networking events. CPhI North America provides a complete list of the program on the conference website.

Source: CPhI North America

Related to this article

View more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more